Analyst Price Target is $3.67
▲ +56.03% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Calithera Biosciences in the last 3 months. The average price target is $3.67, with a high forecast of $5.00 and a low forecast of $2.00. The average price target represents a 56.03% upside from the last price of $2.35.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Calithera Biosciences. This Buy consensus rating has held steady for over two years.
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.